Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
Businesswire·2025-10-22 08:25
合作协议概述 - 武田与信达生物就两种晚期肿瘤药物IBI363和IBI343达成授权与合作协议 [1] - 协议范围涵盖大中华区以外的全球开发、制造和商业化 [1] 合作药物详情 - IBI363正在非小细胞肺癌和结直肠癌中进行评估 [1] - IBI363在其它实体瘤类型中显示出潜在疗效 [1]